Abstract:Background:Glioblastoma (GBM) is a highly aggressive cancer having a dismal prognosis. N6-methyladenosine (m6A) is closely related to GBM progression. The significance of m6A modifications depends on the m6A readers, whose functions in glioma progression are largely unknown. This study sought to investigate the expression of the m6A related gene in glioma and its effect on the malignant progression of glioma.Methods:The expression differences between low-grade gliomas (LGGs) and high-grade gliomas (HGGs), and among 19 m6A-related genes were analyzed by The Cancer Genome Atlas (TCGA). Survival probability was analyzed in terms of the high or low expression of insulin growth factor-2 binding protein 3 (IGF2BP3) in the TCGA data set. The clinicopathological data of 40 patients with glioma were analyzed retrospectively, and the expression of IGF2BP3 in the tumor tissues was analyzed by immunohistochemistry (IHC). Lentiviral vectors harboring short-hairpin RNA (shRNA) were used to knock down IGF2BP3 in the glioma cell lines U87 and U251, and the results were verified by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and western blot. The effects of IGF2BP3 on the proliferation, invasion, and tumorigenicity of the glioma cells were verified by Cell Counting Kit-8 (CCK-8), transwell invasion, and subcutaneous tumorigenesis experiments in nude mice. The cell cycle phases were measured by flow cytometry.Results:The sequencing of TCGA data identified IGF2BP3 as the most significantly altered m6A-related gene. Patients with high IGF2BP3 expression had a significantly reduced survival probability (P<0.001) compared to those with low IGF2BP3 expression. IGF2BP3 was more upregulated in the HGGs than the LGGs. The downregulation of IGF2BP3 inhibited the proliferation, migration, and invasiveness of the glioma cells, and xenograft tumor growth in the mice. According to TCGA data, IGF2BP3 was closely related to cell cycle regulators, such as cyclin-dependent kinase 1 (CDK1) and cell-division cycle protein 20 homologue (CDC20). Further, the knockdown of IGF2BP3 affected the expression of CDK1 and the cell cycle process.Conclusions:IGF2BP3 expression in glioma is positively correlated with tumor grade and enhanced glioma cell proliferation, invasion, and tumorigenicity. IGF2BP3 knockdown decreased the expression of CDK1 and the cell cycle process. The current study showed that IGF2BP3 may serve as a biomarker of prognosis and a therapeutic target in glioma.

N6-methyladenosine enhances the expression of TGF-β-SMAD signaling family to inhibit cell growth and promote cell metastasis

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

IGF2BP2 inhibits invasion and migration of clear cell renal cell carcinoma via targeting Netrin‐4 in an m6A‐dependent manner

IDDF2019-ABS-0290 IGF2BP2 Facilitates Tumor Progression Via an M6a-Dependent Mechanism in Colorectal Carcinoma

EGR2-mediated regulation of m6A reader IGF2BP proteins drive RCC tumorigenesis and metastasis via enhancing S1PR3 mRNA stabilization

BTG2 suppresses renal cell carcinoma progression through N6-methyladenosine

N6-methyladenosine (m6A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1

DMDRMR-Mediated Regulation of M6a-Modified CDK4 by M6a Reader IGF2BP3 Drives Ccrcc Progression.

N 6 -methyladenosine modification of RIMS binding protein 2 promotes head and neck squamous cell carcinoma proliferation and radiotherapy tolerance through endoplasmic reticulum stress

RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner

Stabilization of IGF2BP1 by USP10 Promotes Breast Cancer Metastasis Via CPT1A in an M6a-Dependent Manner

Comprehensive analysis of N6-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer

m6A‐Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis

DMDRMR -Mediated Regulation of m 6 A-Modified CDK4 by m 6 A Reader IGF2BP3 Drives ccRCC Progression

IGF2BPs As Novel M6a Readers: Diverse Roles in Regulating Cancer Cell Biological Functions, Hypoxia Adaptation, Metabolism, and Immunosuppressive Tumor Microenvironment

IGF2BP3 promotes the progression of gastric cancer by activating cGMP-PKG signaling pathway via targeting FBXO32

IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression

N6-methyladenosine Reader IGF2BP3 As a Prognostic Biomarker Contribute to Malignant Progression of Glioma.

The m6A reader IGF2BP1 manipulates BUB1B expression to affect malignant behaviors, stem cell properties, and immune resistance of non-small-cell lung cancer stem cells

The RNA M6a Reader IGF2BP3 Regulates NFAT1/IRF1 Axis-Mediated Anti-Tumor Activity in Gastric Cancer

The m6A Reader IGF2BP2 Promotes Oral Squamous Cell Carcinoma Progression by Maintaining UCA1 Stability